1. Senesco: Clinical Success with Multiple Myeloma

Strange, but welcome news in Senesco Technologies (SNT AMEX) this week. Almost all the news for the past two weeks has been good but he shares do not reflect this news.

On Monday the company announced the results of its pre-clinical trials of its cancer therapy with Celgene’s lenalidomide in which tumor growth in mice had been stabilized and in several cases reversed. Two weeks ago (July 27th) the company announced that the drug, SNST-01 had been granted “orphan drug “status by the FDA for two additional blood cancers, mantle cell and diffuse large B-cell lymphomas. See our Morning Note of Friday July 27, 2012. This will ease clinical trials and increase funding potential for the company.

Written by Michael A. Berry, Ph.D. - [ Discovery Investing Web Site ]

alt

AUSTIN, Texas - August 15, 2012 - (Investorideas.com Newswire) SmallCapVoice.com, Inc. announced today that a new audio interview with PositiveID Corporation (OTCBB: PSID), an emerging growth company and developer of airborne bio-threat detection systems for America's homeland defense industry as well as advanced technologies for diabetes management, is now available. The interview can be heard at http://smallcapvoice.com

SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients' financial news releases.

Read more: Biodefense Stock News; PositiveID's (OTCBB: PSID) Chairman and CEO William J. Caragol Discusses...

Montreal, Quebec, Canada - August 15, 2012 (Investorideas.com Newswire) Sunshine Biopharma Inc. (OTCBB:SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has submitted a manuscript detailing Adva-27a preclinical research results for publication in a peer-reviewed scientific journal. Adva-27a is Sunshine Biopharma’s lead anti-cancer compound which has been shown to be effective at killing multidrug resistant cancer cells in vitro. Multidrug resistant cancer cells do not respond to any of the chemotherapy drugs currently in use for cancer treatment.

Read more: BI0PHARMA STOCK ALERT: SUNSHINE BIOPHARMA (OTCBB: SBFM) REPORTS SUBMISSION OF AN Adva-27a...

(Investorideas.com Newswire) DC Brands International, Inc.,(OTCBB:HRDN) reported in June that Mr. Stephen Horgan, Brand Aspirations Founder and Former Coca-Cola (NYSE:KO)  and Coors Veteran purchased controlling interest of DC Brands International, Inc. /dba/H.A.R.D. Nutrition.

Mr. Horgan said, "After spending the last month assessing the Company and its prospects, and seeking advice and counsel with my peers and colleagues in the industry about the H.A.R.D. Nutrition Brand, I became overwhelmingly encouraged with the feedback I was receiving. I am confident that not only is the health and nutrition conscious consumer waiting for a brand like H.A.R.D. Nutrition, but the retail industry is ready to provide it.

Read more: Beverage Stock DC Brands (OTC: HRDN) Brings Former Coca-Cola (NYSE:KO) and Coors Veteran on Board...

TAMPA, Fla. - August 14, 2012 (Investorideas.com newswire) OTC Healthcare stock alert - Comprehensive Care Corporation (OTCBB: CHCR), a leading behavioral health, substance abuse and psychotropic pharmacy management services provider for managed care companies throughout the U.S., reports earnings of $1.7 million for the six months ended June 30, 2012. Earnings per diluted common share were $0.02. This compares to a $3.9 million loss in the first six months of 2011 and a $.07 loss per common share.

Read more: OTC Healthcare Stock Alert: Comprehensive Care (OTCBB: CHCR) Six Month Financial Results; Revenues...